BeOne Medicines Ltd. (ONC) earnings date
Mar 1, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 37 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | before open | 36 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | before open | 36 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | before open | 36 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | before open | 57 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | before open | 37 | 8-K |
| Q1 FY2025 | Wed, May 7, 2025 | before open | 37 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | before open | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "Raised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP operating income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0 billion SAN CARLOS, Calif. – November 5, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026." exhibit Read from the sentence: revenue $6.9 billion to $7 billion, FY2026 |
| Q3 FY2026 | "Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI." exhibit |
| Q3 FY2026 | "Full Year 2026 Guidance BeOne’s financial guidance is summarized below: Prior FY 2026 Guidance Current FY 2026 Guidance 1 Total revenue $6.6B - $6.8B $6.9B - $7.0B GAAP gross margin % High-80% range High-80% range GAAP operating expenses 2 (combined R&D and SG&A) $4.8B - $5.0B $4.9B - $5.0B GAAP operating income 2 $1.0B - $1.1B $1.2B - $1.3B Non-GAAP operating income 2,3 $1.7B - $1.8B $1.9B - $2.0B 1 Assumes November 1, 2026 foreign exchange rates. 2 Does not assume any potential new, material business development activity or unusual/non-recurring items. 3 Non-GAAP operating income is a financ" exhibit |
| Q3 FY2026 | "BeOne’s total revenue guidance for full year 2026 of $6.9 billion to $7.0 billion reflects performance through the third quarter and the Company’s expectations for the remainder of the year." exhibit |
| Q3 FY2026 | "Income tax outlook : Earnings may provide sufficient positive evidence to reverse certain valuation allowances in 2026, resulting in a material tax benefit when recognized." exhibit |
| Q2 FY2026 | "Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion SAN CARLOS, Calif. – August 5, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter of 2026." exhibit Read from the sentence: revenue $6.6 billion to $6.8 billion, FY2026 |
| Q2 FY2026 | "Updated Full Year 2026 Guidance BeOne’s financial guidance is summarized below: Prior FY 2026 Guidance Current FY 2026 Guidance 1 Total revenue $6.3B - $6.5B $6.6B - $6.8B GAAP gross margin % High-80% range High-80% range GAAP operating expenses 2 (combined R&D and SG&A) $4.7B - $4.9B $4.8B - $5.0B GAAP operating income 2 $750M - $850M $1.0B - $1.1B Non-GAAP operating income 2,3 $1.45B - $1.55B $1.7B - $1.8B 1 Assumes August 1, 2026 foreign exchange rates. 2 Does not assume any potential new, material business development activity or unusual/non-recurring items. 3 Non-GAAP operating income is " exhibit |
| Q2 FY2026 | "BeOne’s total revenue guidance for full year 2026 of $6.6 billion to $6.8 billion includes expectations for strong revenue growth driven by BRUKINSA’s leadership position in the U.S. and continued global expansion in both Europe and other important rest of world markets." exhibit |
| Q2 FY2026 | "Gross margin percentage is expected to be in the high-80% range and includes the impact of product mix and a full year of 2026 productivity improvements." exhibit |
| Q2 FY2026 | "Income tax outlook : Earnings may provide sufficient positive evidence to reverse certain valuation allowances in 2026, resulting in a material tax benefit when recognized; the timing and magnitude of a potential reversal is uncertain; prior to reversal, income tax expense should trend with earnings per historical relationship." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ONC
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ONC
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/ONC/"><img src="https://veritasdata.dev/embed/ONC.svg" alt="ONC earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/ONC/)
Script
<script async src="https://veritasdata.dev/embed/ONC.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ONC"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.